Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Ahn Expands on Advances Made With Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Bekaii-Saab Breaks Down Approach for Navigating Among Available Options in HCC

July 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the rapidly changing hepatocellular carcinoma treatment landscape and shares advice on how he navigates among the available options available for these patients.

Kundranda Covers Key Trials Generating Excitement in Pancreatic Cancer Paradigm

July 16th 2020

Madappa Kundranda, MD, PhD, discusses the significance of the NAPOLI-1 and NAPOLI-3 trials in pancreatic cancer, other exciting ongoing research efforts, and key challenges remaining in the space.

Dr. Abou-Alfa on Remaining Questions With Infigratinib in FGFR2+ Cholangiocarcinoma

July 16th 2020

Ghassan K. Abou-Alfa, MD, discusses the questions that remain with infigratinib in advanced cholangiocarcinoma with FGFR2 gene fusions/translocations.

Surgical Delays Linked With Higher Risk in Some Gastrointestinal Cancers

July 15th 2020

In light of the COVID-19 pandemic, many elective surgical procedures had been cancelled or rescheduled to maximize hospital capacity and prevent unnecessary exposure for patients, but surgical delays might lead to worse outcomes for certain patients with gastrointestinal cancers.

Yoon Highlights Potential Benefit With Second-Line Pembrolizumab, Followed by Subsequent Therapy, in Advanced Gastric/GEJ Cancer

July 14th 2020

Harry H. Yoon, MD, discusses how second-line pembrolizumab, followed by any subsequent therapy is associated with longer overall survival in patients with advanced gastric/gastroesophageal junction cancer.

Data Monitoring Committee Recommends Potential Stop of OPTIMA Trial in HCC

July 13th 2020

The independent data monitoring committee has recommended that Celsion Corporation consider stopping the global, phase 3 OPTIMA trial examining ThermoDox® in combination with radiofrequency ablation for the treatment of patients with hepatocellular carcinoma.

Dr. Ahn on Left- Versus Right-Sided Tumors in CRC

July 13th 2020

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

AMG 510, AbGn-107 Prove to Be Effective, Tolerable in GI Cancers

July 10th 2020

Andrew L. Coveler, MD, discusses the early-phase data with AMG 510 and AbGn-107 in gastrointestinal malignancies.

Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm

July 10th 2020

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

Pant Provides Insight on Key ASCO 2020 Data in Gastrointestinal Malignancies

July 9th 2020

Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific Program.

FDA Issues Complete Response Letter for Pembrolizumab/Lenvatinib in First-Line HCC

July 8th 2020

The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the accelerated approval of pembrolizumab in combination with lenvatinib for the frontline treatment of patients with unresectable hepatocellular carcinoma.

Dr. Bekaii-Saab on Second-Line Treatment Options in HCC

July 8th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Olaparib Approved in Europe for BRCA+ Pancreatic Cancer

July 8th 2020

The European Commission has approved single-agent olaparib as a maintenance treatment for adult patients with germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma who have not progressed after a minimum of 16 weeks of a frontline platinum-based chemotherapy regimen.

Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma

July 3rd 2020

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer

July 3rd 2020

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors

July 3rd 2020

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

July 2nd 2020

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer

July 2nd 2020

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.